|
Group
|
Number of cohorts
|
HR and 95% CI
|
P value
|
Heterogeneity (%)
|
P value for heterogeneity
|
Ratio between subgroups
|
P value between- subgroup
|
|---|
|
Country
|
|
Eastern Countries
|
9
|
0.59 (0.37–0.92)
|
0.021
|
76.3
|
< 0.001
|
0.68 (0.38–1.21)
|
0.189
|
|
Western Countries
|
10
|
0.87 (0.61–1.25)
|
0.455
|
81.6
|
< 0.001
|
|
Study design
|
|
Prospective
|
3
|
0.81 (0.18–3.75)
|
0.792
|
83.7
|
0.002
|
1.16 (0.25–5.38)
|
0.852
|
|
Retrospective
|
16
|
0.70 (0.55–0.89)
|
0.004
|
64.7
|
< 0.001
|
|
Disease status
|
|
Adenocarcinoma
|
6
|
0.65 (0.36–1.18)
|
0.154
|
75.5
|
0.001
|
0.86 (0.43–1.72)
|
0.660
|
|
Both
|
13
|
0.76 (0.53–1.10)
|
0.152
|
86.7
|
< 0.001
|
|
Sample size
|
|
500 or more
|
2
|
0.52 (0.36–0.76)
|
0.001
|
49.4
|
0.160
|
0.68 (0.41–1.10)
|
0.117
|
|
< 500
|
17
|
0.77 (0.56–1.06)
|
0.106
|
81.4
|
< 0.001
|
|
Mean age (years)
|
|
65.0 or older
|
4
|
0.59 (0.36–0.98)
|
0.043
|
73.2
|
0.011
|
0.65 (0.35–1.19)
|
0.160
|
|
< 65.0
|
11
|
0.91 (0.65–1.28)
|
0.595
|
78.0
|
< 0.001
|
|
Percentage male (%)
|
|
50.0 or greater
|
12
|
0.81 (0.55–1.19)
|
0.290
|
86.2
|
< 0.001
|
1.35 (0.82–2.23)
|
0.242
|
|
< 50.0
|
7
|
0.60 (0.43–0.82)
|
0.002
|
42.9
|
0.105
|
|
Percentage of current/past smokers (%)
|
|
50.0 or greater
|
11
|
0.78 (0.52–1.17)
|
0.239
|
87.5
|
< 0.001
|
1.50 (0.64–3.50)
|
0.349
|
|
< 50.0
|
5
|
0.52 (0.25–1.11)
|
0.092
|
81.1
|
< 0.001
|
|
Percentage of patients using TKI (%)
|
|
30.0 or greater
|
9
|
0.60 (0.48–0.75)
|
< 0.001
|
26.2
|
0.211
|
0.59 (0.32–1.10)
|
0.099
|
|
< 30.0
|
4
|
1.01 (0.57–1.81)
|
0.963
|
87.3
|
< 0.001
|
|
Study quality
|
|
High
|
10
|
0.67 (0.50–0.90)
|
0.007
|
58.0
|
0.011
|
0.85 (0.47–1.53)
|
0.585
|
|
Low
|
9
|
0.79 (0.47–1.31)
|
0.357
|
88.3
|
< 0.001
|
- CI confidence intervals, HR hazards ratios, TKI tyrosine kinase inhibitor, bold entries P<0.05
